Foreword ................................................................................................................................................ 4 1.Executive Summary ...................................................................................................................... 6 2.Introduction .................................................................................................................................... 8 2.1.Antimicrobial resistance .......................................................................................................... 8 2.2 Surveillance of antimicrobial resistance .................................................................................. 8 2.3 Jordan National AMR surveillance system (JARSS) .............................................................. 9 3.Methods ........................................................................................................................................ 12 3.1 Data generation ..................................................................................................................... 12 3.2 Data collection ....................................................................................................................... 13 3.3 Data analysis ...................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................结果................................................................................................................................................................................................................................................................................................................................................................................................................................................................................................... 17 4.1患者/孤立特征.........................................................................